NovoCure Beats on Q3 Revenue, Raises 2026 Guidance and Adjusted EBITDA Outlook
NVCR sits 45% above its 52-week low of $9.82.
Summary
NovoCure reported Q3 2026 revenue of $193.4M, up 16%, with adjusted EBITDA of $15.7M, and raised full-year revenue and adjusted EBITDA guidance.
Key Events · Earnings and Guidance · NVCR
-
Q3 Revenue Up 16% to $193.4M
Net revenues rose to $193.4M from $167.2M a year earlier, driven by 19% growth in global active patients to 5,260.
-
Adjusted EBITDA Turns to $15.7M
Adjusted EBITDA was $15.7M versus $(3.0)M in Q3 2025, and net loss narrowed to $10.4M ($0.09 per share) from $37.3M ($0.33).
-
2026 Guidance Raised
Full-year revenue guidance lifted to $736M-$743M from $710M-$725M; adjusted EBITDA guidance lifted to $24M-$34M from $0M-$15M.
-
Balance Sheet and Debt
Cash, cash equivalents and short-term investments totaled $463.5M at September 30, 2026, against a $25.0M current maturity of the senior secured credit facility.
Analysis · NVCR · Industrial Applications And Services
NovoCure delivered $193.4M of Q3 revenue (up 16%) and swung to $15.7M of adjusted EBITDA from a small loss a year ago, then raised full-year revenue guidance to $736M-$743M and adjusted EBITDA to $24M-$34M. The EBITDA raise is the bigger change: the low end moved from $0 to $24M, which puts the company's path to profitability on a firmer footing. Cash of $463.5M against a $25M current debt maturity keeps the balance sheet comfortable, so this is an operating story rather than a financing one. The next hard datapoint is the FDA decision on brain metastases from NSCLC in Q4 2026.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NVCR was trading at $14.25 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $9.82 to $21.45. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.